Edel del
Barco Morillo
Profesor Asociado CC. Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (44)
2024
-
COMPLICATIONS SECONDARY TO THE USE OF SGLT2 INHIBITORS IN ONCOLOGICAL PATIENTS: A SERIES OF 5 CASES
European Journal of Case Reports in Internal Medicine, Vol. 11, Núm. 1
-
Cuidados continuos en Oncología (I): generalidades
Oncología clínica (Arán Ediciones), pp. 147-155
-
Cuidados continuos en oncología (II): control de los principales síntomas y del dolor, cuidados en el final de la vida, duelo
Oncología clínica (Arán Ediciones), pp. 157-173
-
Cuidados continuos en oncología (III): infecciones en el paciente con cáncer, neutropenia febril
Oncología clínica (Arán Ediciones), pp. 175-188
-
Cáncer de cabeza y cuello
Oncología clínica (Arán Ediciones), pp. 259-271
-
Cáncer de pulmón
Oncología clínica (Arán Ediciones), pp. 227-257
-
Diagnóstico nosológico y de extensión. Factores pronósticos
Oncología clínica (Arán Ediciones), pp. 59-71
-
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
International Journal of Molecular Sciences, Vol. 25, Núm. 4
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
2023
-
Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality
Precision Cancer Medicine
-
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
Cancers, Vol. 15, Núm. 17
-
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
Chinese Clinical Oncology, Vol. 12, Núm. 6
-
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128
-
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
Frontiers in Oncology, Vol. 13
-
The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients
Diagnostics, Vol. 13, Núm. 14
2022
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Severe Hyponatremia Masking Central Diabetes Insipidus in a Patient with a Lung Adenocarcinoma
Case Reports in Oncology, Vol. 15, Núm. 1, pp. 91-98
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8